Printer Friendly

LIFECORE BIOMEDICAL ANNOUNCES FIRST QUARTER RESULTS

 LIFECORE BIOMEDICAL ANNOUNCES FIRST QUARTER RESULTS
 CHASKA, Minn., Nov. 7 /PRNewswire/ -- Lifecore Biomedical, Inc.


(NASDAQ: LCBM) today announced revenues of $1,338,000 for the first quarter, a decrease of 8 percent from the same quarter last year. The company also reported a net loss of $866,000 or $.15 per share, compared to a net loss of $267,000, or $.05 per share, for the first quarter last year.
 Lifecore indicated that overall financial results were in line with management's expectations. The decrease in revenues was due to a reduction in oral restorative product sales. Such quarterly fluctuations are anticipated and not expected to impact the long term growth trend.
 Sales of hyaluronate-based products increased from the quarterly period of a year ago.
 The net loss reflects continuing investment in marketing and sales support for the company's Oral Restorative Products Division, as well as costs associated with relocation of the company's manufacturing capability and increased interest expense.
 The Sept. 30, 1991, balance sheet reflects working capital of $15,869,000, including $15,746,000 in cash and cash equivalents. The improvement in working capital and cash is directly attributable to a public offering of the company's common stock which was completed during the quarter ended Sept. 30, 1991.
 Lifecore develops, manufactures and markets sterile medical devices for surgical applications. The company's common stock is traded on the NASDAQ National Market System under the symbol LCBM.
 LIFECORE BIOMEDICAL, INC.
 INCOME STATEMENT DATA
 Three Months Ended
 9/30/91 9/30/90
 Net sales $1,338,000 $1,451,000
 Cost of goods sold 835,000 811,000
 Research and development 211,000 128,000
 Marketing and sales 517,000 451,000
 General and administrative 385,000 341,000
 Manufacturing relocation 179,000 --
 Other income (expense) (77,000) 13,000
 Net loss $(866,000) $(267,000)
 Net loss per share $(.15) $(.05)
 BALANCE SHEET DATA
 9/30/91 6/30/90
 Working capital $15,869,000 $2,203,000
 Total assets 29,558,000 15,744,000
 Long-term debt 7,563,000 7,748,000
 Shareholder's equity 19,074,000 4,500,000
 -0- 11/07/91
 /CONTACT: Colleen M. Olson or James W. Bracke, both of Lifecore Biomedical, 612-368-4300/
 (LCBM) CO: Lifecore Biomedical ST: Minnesota IN: MTC SU: ERN JS-KH -- MN010 -- 2289 11/07/91 14:08 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 7, 1991
Words:388
Previous Article:SOUTHERN COMPANY FINALIZES SETTLEMENT WITH GULF STATES
Next Article:UNION CARBIDE INTRODUCES TECHNOLOGY TO PREVENT ACID RAIN
Topics:


Related Articles
LIFECORE REPORTS SECOND QUARTER RESULTS; POTENTIAL CONTRACT RENEWAL
LIFECORE BIOMEDICAL REPORTS THIRD QUARTER RESULTS
LIFECORE BIOMEDICAL REPORTS FISCAL 1992 RESULTS
LIFECORE BIOMEDICAL REPORTS FIRST QUARTER RESULTS; INCREASED ALCON ORDER
LIFECORE REPORTS RECORD SECOND QUARTER RESULTS
LIFECORE REPORTS RECORD THIRD QUARTER REVENUES
LIFECORE REPORTS FIRST QUARTER FISCAL 1996 FINANCIAL RESULTS
LIFECORE REPORTS THIRD QUARTER FISCAL 1996 FINANCIAL RESULTS
Lifecore Reports First Fiscal Quarter Results
Lifecore Reports Second Fiscal Quarter Results

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters